NYSE: BSX · Industrial Applications and Services · 4 alerts · CIK 885725
Share price
$43.69Close, Nov 16
Market cap
$63.3B
Shares outstanding
1.45BLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Boston Scientific Corp filings on SEC EDGAR ↗
Boston Scientific reported net sales of $5.138 billion for the third quarter of 2026, a slight increase from $5.065 billion in the prior year period. Net income attributable to common stockholders decreased to $582 million ($0.40 per diluted share) compared to $755 million ($0.51 per diluted share) in Q3 2025, impacted by higher operating expenses and litigation-related charges.
Boston Scientific reported Q3 2026 net sales of $5.138 billion, representing 1.5% organic growth despite operational challenges from a previously disclosed cybersecurity incident. The company achieved GAAP EPS of $0.40 and adjusted EPS of $0.73, while continuing to advance its pipeline with new FDA clearances for its StoneSmart and SEISMIQ technologies.
“This has been a challenging year for Boston Scientific and I’m proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients. As we move forward, I remain confident in our long-term strategy, fueled by our dedicated talent, differentiated portfolio and strong pipeline of meaningful innovation.”
Mike Mahoney, chairman and chief executive officer, Boston Scientific
Boston Scientific promoted Joe Fitzgerald to Executive Vice President and Chief Operating Officer, effective January 1, 2027. The company disclosed his new compensation package, including a $1.05 million base salary, a 110% target bonus, and a 2027 annual equity award valued at $7.0 million. The appointment coincides with a new operating structure consisting of three reportable segments: Interventional Therapies, Rhythm Solutions, and MedSurg.
Arthur C. Butcher, Executive Vice President and Group President of MedSurg and Asia Pacific, has announced his retirement effective January 1, 2027. He will serve as a senior advisor through February 26, 2027, maintaining his current annual base salary of $780,000 during the transition period.